“Latest Stem Cells News”

Sheng Ding, the leader of a group of researchers at the Scripps Research Institute of the La Jolla University in California, spoke about using chemistry-related techniques to obtain pluripotent stem cells from a miniscule section of skin at Milan University in a conference on stem cells.

Experts were able to cause some skin cells in mice to regress to their embryonic state by injecting four proteins into an adult mouse without performing any sort of DNA manipulation. A technique that, according to their idea, could be safer than techniques based on genetic manipulation. The cells obtained by intervening directly on DNA have proven to be potentially dangerous since in the long term, they have caused tumors in mice. Acting through proteins (and not through the genes that produce them) should allow this risk to be avoided.

The technique was described in a study published recently in ‘Cell Stem Cell’. Sheng Ding, dressed in a pink shirt, wearing a backpack, and looking like a student, spoke about his research. “Recent discoveries about the biology of stem cells can help us to find new approaches to treat various diseases,” he explained in his speech. “In order to reach these objectives a better comprehension of the mechanisms that control the destiny of stem cells is fundamental, as well as further studies into more efficient methods to manipulate them,” he reflected.

This is the path that Ding and his colleagues have followed in their lab in California: “Our most recent discovery represents a step towards controlling cells and the ‘self restoration’, survival, differentiation, and reprogramming mechanisms of pluripotent stem cells”.

Currently, scientists are faced with “just a promising path to explore. Clinical applications are far from a reality,” specified Fulvio Gandolfi, head of Unistem’s biomedical embryology lab (the stem cell research center of the university of Milan).

Certainly, if initial results are confirmed, he continued “Ding’s discovery would have important repercussions since they would solve a series of difficult ethical questions”. First of all, explained the expert, “we would be able to obtain pluripotent cells without using embryos”. It would suffice to have an adult cell and induce it to regress by using chemical techniques. There is another advantage though: any somatic cell that can regress into an embryonic state can be reprogrammed to replicate into any other human tissue, from heart to nerve cells. “Think about an elderly person who has just suffered a heart attack. We could obtain heart cells just by scraping away a little bit of skin,” observed Gandolfi, “without being forced to remove any damaged heart tissue. The same goes for nerve cells, which are difficult to obtain and subject to the effects of age”

Incoming search terms:

The use of stem cells has often been a controversial issue in the media. International Stem Cell Corp. looks set to tackle the issue head on after launching its own line of stem cell based beauty products. According to reports online the skin care range was created by its wholly owned subsidiary Lifeline Skin Care.

CEO of Lifeline Skin Care, Dr. Ruslan Semechkin, was quoted as saying, “The commercial launch of the new skin care products represents an important step in the execution of ISCO`s strategy.” Plastic surgeon Dr. Gregory S. Keller described the new range as “…a huge step forward in anti-aging skin care products”.

International Stem Cell Corp is based in California. Lifeline skin care develops cosmetics using contain extracts from human parthenogenetic stem cells. The product range includes Defensive Day Moisture Serum and Recovery Night Moisture Serum.

from http://www.carefair.com/html/Stem_Cell_Based_Cosmetics_Launched_10469.html

Incoming search terms:

Two critical programs funded by the California Institute for Regenerative Medicine, the state stem cell agency, got a $11 million increase today when the agency’s 29-member Governing Board voted to approve funding for two additional grants in the Training II program and five additional grants in the Bridges program.

The grants voted in today had been recommended by the Scientific and Medical Research Funding Working Group for funding if funds permit. In January 2009, when the Board considered those applications, they voted to fund only the top tier due to uncertainty in the bond market. With improvements in the state’s bond situation, the Board chose to reconsider the second tier of grants in order to further bolster successful programs training the next generation of stem cell scientists and laboratory staff.

Incoming search terms:

International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to minimize immune-rejection by providing cells that can be immune-matched to large segments of the population.

These products represent milestone achievements in ISCO’s strategy of generating revenue from the sale of research products, while building infrastructure from that effort to expand the manufacturing and quality control capacities ISCO needs to commercialize the therapeutic applications of human parthenogenetic stem cells.

One of its newest and most promising products consist of “xeno-free” human cells and culture reagents that allow researchers to study embryonic stem cells without contamination from animal (non-human) components. These products meet the needs for stem cell research to be done using “human-only” systems. Other products include Lifeline’s living human cells and reagents for research and drug development into cardiovascular, kidney, lung, nerve, eye and skin disease. Lifeline is continuing to develop unique reagents and media for the growing field of stem cell research. The “Lifeline” brand of products consist of human cells and the culture reagents and growth factors needed to grow the cells.

According to Jeffrey Janus, CEO of Lifeline, “We are proud of the quality of our new products, as reflected in the sales growth they are exhibiting in the human cell research markets. We look forward to launching more new products into the growing markets for stem cell research and drug development. These products will contribute to the success of ISCO, not only by supporting ISCO’s therapeutic research, but also through the development of critical manufacturing and quality control systems necessary for ISCO to produce therapeutic human cells in the future.”

Lifeline’s products can be found at www.lifelinecelltech.com
For more news and information on International Stem Cell Corporation please visit www.IRGnews.com/coi/ISCO where you can find the CEO’s video, a fact sheet on the company, investor presentations, and more.

from http://www.internationalstemcell.com

Incoming search terms: